MRE11 Lactylation and Saikosaponin D: Overcoming Radioresistance in Triple-Negative Breast Cancer

Study Background and Research Question

Triple-negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer, characterized by the absence of estrogen, progesterone, and HER2 receptors. TNBC accounts for approximately 17% of all breast cancer cases and is associated with poor prognosis due to high rates of metastasis and recurrence. Radiotherapy remains a cornerstone for TNBC management, yet the emergence of radioresistance significantly limits its therapeutic efficacy. Although metabolic reprogramming—especially enhanced glycolysis and the resulting lactate accumulation—has been implicated in therapy resistance, the underlying molecular mechanisms connecting metabolic changes to DNA repair and radioresistance have remained elusive.

Key Innovation from the Reference Study

The reference study provides compelling evidence that endogenous lactate accumulation in radioresistant TNBC cells promotes DNA repair through a specific post-translational modification: lactylation of the DNA repair protein MRE11 at lysine 673 (K673). This modification enhances MRE11’s function in double-strand break (DSB) repair, thereby conferring resistance to radiation-induced damage. Importantly, the study identifies histone deacetylase 5 (HDAC5) as the delactylase responsible for reversing this modification and demonstrates that Saikosaponin D (SSD) sensitizes TNBC cells to radiation by upregulating HDAC5 via the HIF1α pathway. This mechanistic insight establishes the MRE11-HDAC5 axis as a novel and actionable target for overcoming radioresistance in TNBC.

Methods and Experimental Design Insights

The investigators employed a multifaceted approach that integrated metabolite manipulation, gene editing, proteomics, and clinical sample analysis. Key methodological elements included:

• Metabolic Modulation: TNBC cell lines were treated with exogenous lactate or the glycolysis inhibitor oxamate to assess the impact of lactate flux on DNA damage and repair after irradiation.
• Genetic Tools: Lentiviral constructs encoding wild-type and mutant MRE11, as well as HDAC5 overexpression and knockdown vectors, enabled precise interrogation of protein function and modification status.
• Proteomics-MS and Western Blotting: Mass spectrometry and immunoblotting were used to quantify MRE11 lactylation and to profile protein interactions.
• ChIP-qPCR and Luciferase Reporter Assays: To dissect the regulation of HDAC5, chromatin immunoprecipitation and promoter activity assays were performed to map HIF1α binding sites on the HDAC5 promoter.
• Bioinformatic Analysis: Clinical relevance was established through TCGA data mining and tissue microarrays, confirming HDAC5 downregulation in TNBC specimens.

This comprehensive design allowed the authors to link metabolic changes, post-translational modifications, protein–protein interactions, and transcriptional regulation in the context of radioresistance.

Core Findings and Why They Matter

Several pivotal discoveries emerged from the study:

• Lactate-dependent MRE11 Lactylation: Elevated lactate in radioresistant TNBC cells increased MRE11 K673 lactylation, which in turn facilitated more efficient DNA DSB repair following irradiation.
• HDAC5 as a MRE11 Delactylase: HDAC5 was shown to directly interact with MRE11 and remove the lactyl group from K673, reducing DNA repair capacity and sensitizing cells to radiation. Docking and co-immunoprecipitation validated this biochemical interaction.
• SSD Modulates the HIF1α/HDAC5 Axis: Saikosaponin D upregulated HIF1α, which binds to a specific region of the HDAC5 promoter (-342bp to -20bp), driving HDAC5 expression and MRE11 delactylation. This process enhanced radiosensitivity in TNBC models both in vitro and in clinical samples.
• Clinical Corroboration: Analysis of patient samples and TCGA datasets confirmed that HDAC5 levels are reduced in TNBC, supporting the translational relevance of targeting this axis.

Collectively, these findings elucidate a mechanistic bridge between metabolic reprogramming and DNA repair, suggesting that targeting protein lactylation may be an effective strategy to overcome therapy resistance in aggressive tumors.

Comparison with Existing Internal Articles

Several recent reviews and protocols focus on the intersection of lactate metabolism, histone lactylation, and therapeutic resistance:

• The article "Sodium Oxamate: Targeting Tumor Bioenergetics and Resistance" discusses how sodium oxamate—an LDH-A inhibitor and structural analogue of pyruvate—can disrupt glycolytic flux and reduce lactate-driven DNA repair, echoing the metabolic manipulation used in the reference study.
• "Sodium Oxamate in Cancer Metabolism: Protocols & Troubleshooting" provides workflow guidance for implementing oxamate in metabolic reprogramming studies, including protocols for modeling radioresistance and analyzing histone lactylation as a functional readout.
• Notably, while studies such as "Microglial H3K18 Lactylation Protects White Matter After ICH" have demonstrated a neuroprotective role for lactylation in brain injury, the current reference highlights the context-dependent impact of lactylation: in TNBC, MRE11 lactylation supports tumor survival under therapeutic stress, underscoring the need for targeted metabolic intervention.

These internal resources reinforce the value of integrating metabolic inhibitors and lactylation analysis in cancer metabolism research, while also illustrating the diverse consequences of lactylation in different disease models.

Limitations and Transferability

While the study provides robust mechanistic and translational evidence, certain limitations should be considered:

• Preclinical Models: The majority of experiments were performed in cell lines and patient-derived tissue arrays; in vivo validation and clinical trials will be necessary to confirm efficacy and safety of SSD or HDAC5-targeted approaches.
• Tumor Heterogeneity: As metabolic reprogramming and DNA repair pathways can vary among TNBC subtypes and between patients, the generalizability of the MRE11-HDAC5 axis as a universal target warrants further study.
• Contextual Role of Lactylation: Given that lactylation can play protective roles in other tissues (e.g., neuroprotection post-ICH), therapeutic targeting may require precision delivery or careful selection of patient cohorts to avoid off-target effects.

Overall, the concept of targeting metabolic-epigenetic crosstalk is transferable to other aggressive cancers exhibiting high glycolytic activity, but translational progress will depend on further validation and optimization.

Protocol Parameters

• Lactate supplementation: 10–20 mM treatment for 24–48 hours to model enhanced glycolytic flux and assess lactylation-dependent DNA repair.
• Sodium Oxamate pretreatment: 5–20 mM, 2–24 hours before irradiation, as a glycolysis inhibitor to reduce endogenous lactate and test its impact on DNA repair efficiency (see protocol guidance).
• HDAC5 overexpression/knockdown: Lentiviral transduction at MOI 10–50, 48–72 hours before experimental readout.
• ChIP-qPCR for HIF1α binding: Use primers spanning –342bp to –20bp of the HDAC5 promoter to confirm transcriptional regulation.
• Assessment of MRE11 lactylation: Immunoblot for K673-lactylated MRE11, with normalization to total MRE11 and histone H3 (as loading control).

Experimental values should be tailored to specific cell lines and validated for each workflow.

Research Support Resources

Researchers aiming to dissect metabolic reprogramming and lactylation-mediated DNA repair in cancer models can utilize Sodium Oxamate (SKU C3893) as a competitive inhibitor of LDH-A to modulate glycolytic flux and lactate levels. According to the product information, sodium oxamate is water-soluble and widely used in tumor bioenergetics studies, supporting workflows similar to those outlined in the reference study. For protocols and troubleshooting strategies, refer to recent workflow articles or consult APExBIO’s technical resources.